###### Strengths and limitations of this study

-   This is the first large-scale and representative study that vividly described maternal adherence to micronutrient supplementation before and during pregnancy in Northwest China.

-   Sample representativeness in Shaanxi was guaranteed by a large sample of 28 678 women that were recruited using a stratified multistage random sampling method.

-   The results could be generalised in Northwest China and may also reflect the universality of the problem in China and could serve as a basis for developing health education strategies in the future.

-   Recall bias was ineluctable because the information was self-reported by retrospection.

-   The study does not provide an insight into the dosage of specific micronutrient supplementation due to the uncertain specifications of some reported supplements.

Introduction {#s1}
============

Pregnancy is a state in which macronutrient and micronutrient requirements increase due to maternal physiological changes and fetal growth.[@R1] During pregnancy, adequate micronutrient intake is difficult to achieve from daily diet,[@R2] and maternal micronutrient deficiencies could cause severe adverse outcomes, including stillbirth, low birth weight (LBW) and birth defects.[@R3] Micronutrient supplementation is an alternative, in addition to the adjustment of diet pattern and quality, to fulfil the increased nutrition demands during pregnancy.[@R4] In recent decades, maternal micronutrient supplementation during pregnancy has attracted much attention, as growing evidence has shown that it has significant benefits in the improvement of maternal health status as well as birth outcomes.[@R5] As a result, some micronutrients that greatly contribute to maternal and fetal health are highly recommended for routine use during pregnancy. Many countries have implemented periconceptional folic acid (FA) supplementation to protect against neural tube defects (NTDs).[@R9] WHO has also provided several guidelines for micronutrient supplementation for pregnant women.[@R11] Daily use of FA (400 µg), starting from 2 months before the planned pregnancy to 12 weeks of pregnancy, is recommended for the prevention of NTDs;[@R12] daily oral FA combined with iron supplementation (400 µg FA and 30--60 mg iron) throughout pregnancy is recommended to reduce the risk of LBW, maternal anaemia and iron deficiency;[@R13] daily oral calcium supplementation (1.5--2.0 g) in the second half of pregnancy is recommended for pregnant women in the area of low dietary calcium intake to reduce the risk of pre-eclampsia.[@R14]

China is the most populated developing country with a considerable incidence of adverse pregnancy outcomes, including maternal anaemia,[@R15] LBW[@R16] and small for gestational age (SGA).[@R8] However, the implementation of FA supplementation project (take daily FA (400 µg), start from 3 months before pregnancy to the end of the first trimester) to prevent NTDs, especially in rural areas, is the only nutritional intervention promoted by the Chinese Health Ministry (now the Chinese National Health Commission) for pregnant women and women planning to be pregnant.[@R17] Also, the only routine antenatal micronutrient supplementation recommended by the Chinese Nutrition Society (CNS) for women of childbearing age is the daily use of FA (400 µg), starting from 3 months before the planned pregnancy until the end of pregnancy.[@R19] No more guidelines for routine supplementation of other micronutrients exist so that the use of micronutrient supplements during pregnancy varied in Chinese geographic areas and socioeconomic groups.[@R4]

All health policies and recommendations of micronutrient supplementation for pregnant women emphasise the timing, dosage, sustainability of use as well as the target population. Evidence showed that low compliance was a major reason for the low effectiveness of micronutrient supplementation during pregnancy[@R8] and thus the exploration of the determinants of the adherence is important for guiding the appropriate use to guarantee the efficacy. Many factors were reported in relation to maternal adherence to micronutrient supplementation before and during pregnancy, including maternal age, educational background, occupation and antenatal care. Previous studies have reported on the compliance of maternal micronutrient supplementation in Western countries like the USA and Norway[@R22] as well as in Africa countries like Ethiopia and Kenya.[@R24] Few of the studies focused on maternal adherence to micronutrient supplementation before and during pregnancy in China.

Shaanxi Province is a developing area in Northwest China where most of the micronutrients derived from diet among pregnant women were lower than the Chinese recommended nutrient intake (RNI),[@R26] especially the intake of folate and calcium.[@R26] Although dietary iron intake was close to the RNI for the first and second trimester, most iron from diet were the non-heme iron, which is not efficiently absorbed and used by the human body.[@R28] Additionally, about 40% of women of childbearing age in the region suffered anaemia,[@R29] and the incidence of adverse birth outcomes, including LBW and preterm birth, was high in this region.[@R30] Therefore, maternal micronutrient supplementation seems to be a relatively inexpensive and low risk method for compensating for inadequate dietary intake during pregnancy and improving the health status of local mothers and fetus. However, a representative data from a large-scale study on the maternal micronutrient supplementation before and during pregnancy in this region are not available. Accordingly, this article aims to investigate the condition of maternal micronutrient supplementation before and during pregnancy in Shaanxi, focusing on analysing the rates and associated factors of maternal adherence to supplement consumptions according to existing recommendations and to provide evidence for future evaluation of health policy effectiveness and development of health education strategies.

Methods {#s2}
=======

Data source and participants {#s2-1}
----------------------------

The study used data from a large-scale population-based cross-sectional survey, which was conducted between August and November 2013 in the Shaanxi province with the purpose of investigating the prevalence and risk factors of birth defects among newborns, along with maternal dietary conditions and nutritional supplements use. The target population was women aged from 16 to 49 years, who were pregnant between 2010 and 2013 and had specific pregnancy outcomes before the survey. The sample was acquired from 20 counties and 10 districts of Shaanxi by applying a stratified multistage random sampling method.[@R27] First, 20 counties and 10 districts were randomly selected from the 80 rural counties and 24 urban districts in Shaanxi Province according to the difference in size, distribution and fertility rates of population between rural and urban areas. Subsequently, in the rural area, 6 townships, 6 villages and 30 eligible women were randomly selected from each sampled county, selected township and selected village, respectively. In the urban areas, 3 streets, 6 communities and 60 eligible women were randomly selected from each sampled district, selected street and selected community, respectively. Data collection was completed with structured-questionnaires via in-person surveys by trained interviewers. Information gathered included maternal sociodemographic characteristics, lifestyle, health condition, healthcare utilisation and supplement consumption. A strict quality control process was used to guarantee data integrity and accuracy.[@R27]

A total of 30 027 women were enrolled in the survey after they signed the informed consent, and women with limited cognitive capacity had been excluded. In order to obtain more accurate analysis results, we further excluded 1349 women who did not provide clear information about maternal nutritional supplementation (among them, 761 women had no live birth babies in this pregnancy and refused to provide detailed information). In total, 28 678 women were chosen for the final analysis.

Maternal sociodemographic characteristics, parity and antenatal care information {#s2-2}
--------------------------------------------------------------------------------

Maternal age at delivery was divided into three categories (\<25, 25--34 and ≥35 years), as well as educational level (Junior high school or below, Senior high school and College and beyond), geographical area (Southern Shaanxi, Central Shaanxi and Northern Shaanxi) and per capita annual household income (Low: \<8800, Medium: 8800--15 200 and High: ≥15 200 Yuan, where 1 Yuan=\$0.149 on 17 March 2019). Residence (urban and rural) and parity (primiparous and multiparous) were classified into two categories each. We also investigated the antenatal care information, including the number of antenatal visits (\<5 and ≥5), the type of hospitals for antenatal visit (hospitals below the county level and county level hospitals or above) and pregnancy consultation (yes and no, referred to the participation of health counselling that related to maternal healthcare and fetal development before or during pregnancy).

Micronutrient supplementation {#s2-3}
-----------------------------

Information about micronutrient supplements in tablet and capsule forms was mainly collected. We asked the participants to choose the supplements they used before or during pregnancy from a list of brands of supplements that were commonly provided in the local hospital or pharmacy and to further tell the brand and kind of supplement they consumed, if it was not shown in the list. We did not list iron-FA supplements in the questionnaire, since few supplements on the market were two-nutrient formulations of iron and FA. In the analysis, FA supplements referred to those that only contained FA; iron supplements referred to those that only contained iron; calcium supplements referred to those that contained calcium or calcium with another micronutrient (including calcium-vitamin D and calcium-zinc); multiple-micronutrient (MMN) supplements referred to those that contained FA, iron and other micronutrients. Women who consumed any micronutrient supplement before or during pregnancy were considered as micronutrient supplement users; otherwise, they were regarded as non-users.

We further obtained the time and duration of use of each supplement they reported. The participants were required to select the time of supplement use from the four pregnancy periods (3 months before the last menstrual period, the first trimester, the second trimester and the third trimester) and report the duration of supplementation for each supplement they used. The 3 months before the last menstrual period was defined as the preconceptional period; the time from the 3 months before the last menstrual period to the end of ﬁrst trimester was defined as the periconceptional period; the time of the second and third trimester was defined as the after-periconceptional period.

Adherence to micronutrient supplementation before and during pregnancy was determined by the start time and duration of use according to Chinese guidelines (for FA) and WHO recommendations (for iron, calcium and MMN). Although WHO did not universally recommend MMN supplementation (MMS) for pregnant women, due to its components of iron and FA, we still examined the compliance of MMS by referencing the WHO recommendation for iron and FA supplementation. We considered the duration of use instead of the total amounts, because most of the supplements of interest were taken as one tablet daily. In the present study, the thresholds used to define the adhered duration of use were 180 days for FA and 90 days for others. Therefore, high adherence to FA supplementation was defined as starting from the periconceptional period with ≥180 days of use; otherwise, it was regarded as low adherence. High adherence to iron supplementation was considered as starting from the first trimester with ≥90 days of use; otherwise, it was regarded as low adherence. For calcium supplementation, 20 weeks of gestation was the start time recommended by WHO. Since we did not collect the specific weeks of gestation of micronutrient supplementation, high adherence to calcium supplementation was considered as starting from the second trimester with ≥90 days of use; otherwise, it was regarded as low adherence. High adherence to MMS was defined as one starting from the first trimester with ≥90 days of use; otherwise, it was considered as low adherence.

Statistical analysis {#s2-4}
--------------------

Dataset was established using Epidata 3.1 (The Epidata Association, Odense, Denmark) with double entry. Multiple imputation was used to attribute values for the missing variables, including income level (n=5830), maternal age group (n=434) and the type of hospital for antenatal visits (n=327), taking education level, geographic area, residence, parity, the number of antenatal visits and pregnancy consultation as covariates with five imputed data sets.[@R32] Numbers and percentages (n (%)) were estimated for reporting the rate of micronutrient supplementation in different groups and for presenting the adherence to micronutrient supplementation. Comparisons between groups were completed by either the χ² test or Fisher\'s exact test.

Because of the hierarchical structure of the data derived from the stratified multistage random sampling design, multivariable generalised estimating equation (GEE) models[@R33] with random effect at county level were applied to estimate adjusted OR and 95% CI for factors associated with maternal adherence to micronutrient supplementation before and during pregnancy. Maternal characteristics including age, education, residence, income, parity, pregnancy consultation, number of antenatal visits and type of hospital for antenatal visits were the fixed effects in the GEE models. Binomial distribution, logit link function and an exchangeable covariance structure were used in the GEE analysis. Model 1 analysed the relationship between the adherence to micronutrient supplementation and the sociodemographic characteristics including age, education, residence and income. Model 2 analysed the relationship between the adherence to micronutrient supplementation and sociodemographic characteristics (all the variables in model 1), as well as parity and antenatal care characteristics. The criteria for statistical significance was p\<0.05. All analyses were performed using SAS V.9.4 (SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Maternal characteristics according to micronutrient supplementation before and during pregnancy {#s3-1}
-----------------------------------------------------------------------------------------------

Significant differences existed in aspects of maternal sociodemographic conditions, birth history and antenatal care characteristics between users and non-users of micronutrient supplements before and during pregnancy ([table 1](#T1){ref-type="table"}). Users of micronutrient supplements were more likely to be aged from 25 to 34 years, be better educated, have higher income level, live in central Shaanxi, be rural residents, be primiparous and have better antenatal care (including pregnancy consultations, higher-level hospital for antenatal visits and a higher frequency of antenatal visits).

###### 

Maternal characteristics according to micronutrient supplementation before and during pregnancy among Chinese women in Shaanxi, 2010--2013

  Characteristics                                  Micronutrient supplementation                           
  ------------------------------------------------ ------------------------------- ------ ------ --------- ---------
  *Sociodemographic characteristics*                                                                       
  Age (years)                                                                                              \<0.001
   \<25                                            7843                            32.6   1615   34.9      
   25--34                                          14 299                          59.5   2465   53.3      
   ≥35                                             1909                            7.9    547    11.8      
  Education                                                                                                \<0.001
   Junior high school or below                     14 113                          58.7   3611   78.0      
   Senior high school                              5114                            21.3   627    13.6      
   College and beyond                              4824                            20.0   389    8.4       
  Geographic area                                                                                          \<0.001
   Southern Shaanxi                                5099                            21.2   776    16.8      
   Central Shaanxi                                 13 731                          57.1   1725   37.3      
   Northern Shaanxi                                5221                            21.7   2126   45.9      
  Residence                                                                                                \<0.001
   Rural                                           15 846                          65.9   3455   74.7      
   Urban                                           8205                            34.1   1172   25.3      
  Per capita annual household income (RMB)                                                       \<0.001   
   Low                                             7990                            33.2   1714   37.0      
   Medium                                          7819                            32.5   1604   34.7      
   High                                            8242                            34.3   1309   28.3      
  *Birth history and antenatal care information*                                                           
  Parity                                                                                                   \<0.001
   Primiparous                                     14 651                          60.9   2152   46.5      
   Multiparous                                     9400                            39.1   2475   53.5      
  Pregnancy consultation†                                                                                  \<0.001
   No                                              17 404                          72.4   3981   86.0      
   Yes                                             6647                            27.6   646    14.0      
  The number of antenatal visits                                                                           \<0.001
   \<5                                             6310                            26.2   2298   49.7      
   ≥5                                              17 741                          73.8   2329   50.3      
  Type of hospitals for antenatal visits                                                         \<0.001   
   Township hospitals                              2783                            11.6   622    13.4      
   County hospitals or above                       21 268                          88.4   4005   86.6      

\*P values for the differences among groups were derived from either the χ^2^ tests or Fisher\'s exact test.

†Referred to the participation of health counselling that related to maternal healthcare and fetal development before or during pregnancy.

Rates of and the adherence to micronutrient supplementation before and during pregnancy {#s3-2}
---------------------------------------------------------------------------------------

In total, 83.9% of women took at least one kind of micronutrient supplement before or during their last pregnancy. The main supplements used by participants were FA (67.6%), calcium (57.5%), MMN (14.0%) and iron (5.4%) ([table 2](#T2){ref-type="table"}). Although FA had a relatively higher rate of use during the periconceptional period (64.5%), only 7.4% of women continued usage from the periconceptional period for longer than 180 days. Most of the users started taking calcium supplements during the second trimester (39%), but only 11.7% met the recommended standards after taking the duration of use into consideration. Comparing with the rates of those who began to use iron or MMN in the after-periconceptional period (3.7% for iron and 8.2% for MMN), smaller proportion of women started consumption from the first trimester (1.7% for iron and 5.8% for MMN) and few of them adhered to use of iron or MMN in more than 90 days (0.6% for iron and 2.7% for MMN) ([table 3](#T3){ref-type="table"}). We also found that very few women (0.2%) consumed FA and iron starting from the first trimester with more than 90 days of use (not shown in table). We further examined the adherence to supplementation of FA, iron and FA with iron by taking the contribution of MMS into consideration. Still, the rates of compliant use were low (8.5% for FA, 3.2% for iron and 2.9% for FA with iron, not shown in table).

###### 

Rates of maternal micronutrient supplementation before and during pregnancy among Chinese women in Shaanxi, 2010--2013

  Micronutrient supplements   n        \%
  --------------------------- -------- ------
  Folic acid                  19 352   67.6
  Calcium                     16 414   57.5
  Multiple micronutrient      4018     14.0
  Iron                        1547     5.4
  Vitamin C                   1147     4.0
  B Vitamins                  814      2.8
  Vitamin E                   173      0.6
  Others\*                    1271     4.4

\*Including vitamin A, vitamin D and fish oil.

###### 

Maternal micronutrient supplementation recommendations from WHO and CNS; rates of main micronutrient supplementation by start time and duration of use and adherence to micronutrient supplementation before and during pregnancy among Chinese women in Shaanxi, 2010--2013

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               FA\                                                                                     Iron\                                                                                                            Calcium\                                                        MMN\
                                                               (n=28 629)                                                                              (n=28 644)                                                                                                       (n=28 548)                                                      (n=28 628)
  ------------------------------------------------------------ --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------
  *Recommendations*                                                                                                                                                                                                                                                                                                                     

  WHO recommendation                                           1\. Purpose: NTDs prevention\                                                           Purpose: pregnancy outcome improvement\                                                                          Purpose: pre-eclampsia prevention\                              N/A
                                                               Settings: all\                                                                          Settings: all\                                                                                                   Settings: areas with low calcium intake\                        
                                                               Supplementation: daily use of FA (400 µg)\                                              Supplementation: daily use of iron (30--60 mg)-FA (400 µg)\                                                      Supplementation: daily use of calcium (1.5--2.0 g)\             
                                                               Duration: start at 2 months before the planned pregnancy until 12 weeks of pregnancy\   Duration: throughout pregnancy                                                                                   Duration: from 20 weeks' gestation until the end of pregnancy   
                                                               2. See recommendation for iron and FA supplementation in the right column                                                                                                                                                                                                

  CNS recommendation                                           Purpose: NTDs prevention and pregnancy outcome improvement\                             No routine iron supplementation is recommended for pregnant women;\                                              N/A                                                             N/A
                                                               Settings: all regions in China\                                                         Pregnant women with severe anaemia should appropriately take iron supplements under the guidance of physicians                                                                   
                                                               Supplementation: daily use of FA (400 µg)\                                                                                                                                                                                                                               
                                                               Duration: start at 3 months before the planned pregnancy until the end of pregnancy                                                                                                                                                                                      

  *Micronutrient supplementation in our population (n (%))*                                                                                                                                                                                                                                                                             

  Start at periconceptional period                             18 469 (64.5)                                                                           499 (1.7)                                                                                                        5292 (18.5)                                                     1665 (5.8)

   Start at 3 month before pregnancy                           4966 (17.4)                                                                             79 (0.3)                                                                                                         272 (1.0)                                                       212 (0.8)

    \<90 days (180 days for FA)                                3373 (11.8)                                                                             35 (0.1)                                                                                                         104 (0.4)                                                       81 (0.3)

    ≥90 days (180 days for FA)                                 1593 (5.6)                                                                              44 (0.2)                                                                                                         168 (0.6)                                                       131 (0.5)

   Start at first trimester                                    13 503 (47.2)                                                                           420 (1.5)                                                                                                        5020 (17.6)                                                     1453 (5.1)

    \<90 days (180 days for FA)                                12 992 (45.4)                                                                           243 (0.9)                                                                                                        2291 (8.0)                                                      683 (2.4)

    ≥90 days (180 days for FA)                                 511 (1.8)                                                                               177 (0.6)                                                                                                        2729 (9.6)                                                      770 (2.7)

  Start at after-periconceptional period                       883 (3.1)                                                                               1048 (3.7)                                                                                                       11 122 (39.0)                                                   2353 (8.2)

   Start at second trimester                                   737 (2.6)                                                                               633 (2.2)                                                                                                        8947 (31.4)                                                     1844 (6.4)

    \<90 days                                                  524 (1.8)                                                                               454 (1.6)                                                                                                        5614 (19.7)                                                     1238 (4.3)

    ≥90 days                                                   213 (0.7)                                                                               179 (0.6)                                                                                                        3333 (11.7)                                                     606 (2.1)

   Start at third trimester                                    146 (0.5)                                                                               415 (1.5)                                                                                                        2175 (7.6)                                                      508 (1.8)

    \<90 days                                                  127 (0.4)                                                                               365 (1.3)                                                                                                        1810 (6.3)                                                      435 (1.5)

    ≥90 days                                                   19 (0.1)                                                                                50 (0.2)                                                                                                         365 (1.3)                                                       73 (0.3)

  *Adherence to micronutrient supplementation (n (%))***\***                                                                                                                                                                                                                                                                            

   Low adherence                                               26 525 (92.7)                                                                           28 467 (99.4)                                                                                                    25 215 (88.3)                                                   27 858 (97.3)

   High adherence                                              2104 (7.4)                                                                              177 (0.6)                                                                                                        3333 (11.7)                                                     770 (2.7)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*High adherence to FA supplementation was defined as starting from the periconceptional period with ≥180 days of use; otherwise, it was regarded as low adherence. High adherence to iron supplementation was considered as starting from the first trimester with ≥90 days of use; otherwise, it was regarded as low adherence. High adherence to calcium supplementation was considered as starting from the second trimester with ≥90 days of use; otherwise, it was regarded as low adherence. High adherence to MMS was defined as starting from the first trimester with ≥90 days of use; otherwise, it was considered as low adherence.

FA, folic acid; MMN, multiple-micronutrients; CNS, Chinese Nutrition Society.

Factors associated with the adherence to micronutrient supplementation before and during pregnancy {#s3-3}
--------------------------------------------------------------------------------------------------

[Table 4](#T4){ref-type="table"} shows the results of multivariable GEE models. Higher educational levels (eg, FA: Senior high school vs Junior high school or below: OR 1.38, 95% CI 1.18 to 1.61; College and beyond vs Junior high school or below: OR 2.59, 95% CI 2.21 to 3.05), higher income levels (eg, FA: High vs Low: OR 1.27, 95% CI 1.11 to 1.45), urban residence (eg, FA: Urban vs Rural: OR 1.72, 95% CI 1.08 to 2.72) and better antenatal care (including pregnancy consultation (eg, FA: Yes vs No: OR 1.91, 95% CI 1.71 to 2.14) and a higher frequency of antenatal visits (eg, FA: ≥5 times vs \<5 times: OR 1.59, 95% CI 1.35 to 1.87)) were associated with high adherence to micronutrient supplementation before and during pregnancy. Compared with women below 25 years, women aged from 25 to 34 years were more likely to have high adherence to the supplementation of FA (OR 1.30, 95% CI 1.11 to 1.52), iron (OR 1.49, 95% CI 1.18 to 1.88) and MMN (OR 1.38, 95% CI 1.12 to 1.71). Women above 35 years were associated with a lower probability of high adherence to calcium supplementation (OR 0.71, 95% CI 0.62 to 0.81). Being multipara was less likely related to high adherence to FA supplementation (OR 0.70, 95% CI 0.58 to 0.84). The type of hospital for antenatal visits was not linked to the adherence to micronutrient supplementation.

###### 

Rates of high adherence to micronutrient supplementation before and during pregnancy by maternal characteristics and adjusted OR (95% CI) for factors associated to the high adherence among Chinese women in Shaanxi, 2010-2013\*

  Characteristics                                             n        FA     Iron                   Calcium   MMN                                                         
  ----------------------------------------------------------- -------- ------ ---------------------- --------- ---------------------- ------ ---------------------- ------ ----------------------
  *Sociodemographic characteristics (Model 1)*‡                                                                                                                            
  Age (years)                                                                                                                                                              
   \<25                                                       9458     5.3    Ref                    0.4       Ref                    11.2   Ref                    1.7    Ref
   25--34                                                     16 764   8.7    1.30 (1.11 to 1.52)§   0.7       1.49 (1.18 to 1.88)§   12.4   1.03 (0.94 to 1.12)    3.3    1.38 (1.12 to 1.71)§
   ≥35                                                        2456     6.3    1.22 (0.98 to 1.51)    0.6       1.54 (0.80 to 2.99)    8.6    0.71 (0.62 to 0.81)§   2.3    1.24 (0.84 to 1.84)
  Education                                                                                                                                                                
   Junior high school or below                                17 724   4.9    Ref                    0.4       Ref                    9.9    Ref                    1.6    Ref
   Senior high school                                         5741     7.3    1.38 (1.18 to 1.61)§   0.9       2.00 (1.36 to 2.96)§   13.8   1.32 (1.22 to 1.42)§   2.8    1.51 (1.21 to 1.88)§
   College and beyond                                         5213     15.9   2.59 (2.21 to 3.05)§   1.2       1.69 (1.12 to 2.54)§   15.5   1.45 (1.31 to 1.60)§   6.2    2.65 (2.14 to 3.28)§
  Residence                                                                                                                                                                
   Rural                                                      19 301   5.9    Ref                    0.4       Ref                    10.6   Ref                    2.1    Ref
   Urban                                                      9377     10.4   1.72 (1.08 to 2.72)§   1.1       1.88 (1.17 to 3.01)§   14.0   1.21 (0.90 to 1.62)    3.9    1.30 (0.82 to 2.06)
  Per capita annual household income (RMB)                                                                                                                                 
   Low                                                        9689     5.0    Ref                    0.4       Ref                    10.6   Ref                    1.8    Ref
   Medium                                                     9402     6.4    1.07 (0.94 to 1.23)    0.5       1.06 (0.74 to 1.54)    11.7   1.08 (0.99 to 1.19)    2.2    1.18 (0.96 to 1.45)
   High                                                       9538     10.7   1.27 (1.11 to 1.45)§   1.0       1.56 (1.05 to 2.32)§   12.8   1.09 (0.96 to 1.24)    4.0    1.39 (1.11 to 1.76)§
  *Birth history and antenatal care information (Model 2)*¶                                                                                                                
  Parity                                                                                                                                                                   
   Primiparous                                                16 803   9.2    Ref                    0.7       Ref                    12.8   Ref                    3.2    Ref
   Multiparous                                                11 875   4.8    0.70 (0.58 to 0.84)§   0.5       0.90 (0.61 to 1.34)    10.1   1.02 (0.94 to 1.11)    1.9    0.88 (0.72 to 1.07)
  pregnancy consultation                                                                                                                                                   
   No                                                         21 385   5.6    Ref                    0.5       Ref                    10.7   Ref                    2.3    Ref
   Yes                                                        7293     12.6   1.91 (1.71 to 2.14)§   1.0       1.40 (1.21 to 1.96)§   14.7   1.22 (1.10 to 1.34)§   3.8    1.40 (1.17 to 1.67)§
  The number of antenatal visits                                                                                                                                           
   \<5                                                        8608     3.8    Ref                    0.3       Ref                    7.6    Ref                    15.4   Ref
   ≥5                                                         20 070   8.9    1.59 (1.35 to 1.87)§   0.8       1.66 (1.18 to 2.34)§   13.4   1.41 (1.25 to 1.60)§   26.4   1.33 (1.09 to 1.62)§
  Type of hospitals for antenatal visits                                                                                                                                   
   Township hospitals                                         3405     5.9    Ref                    0.5       Ref                    9.6    Ref                    1.7    Ref
   County hospitals or above                                  25 273   7.6    1.14 (0.94 to 1.37)    0.6       1.26 (0.79 to 2.01)    12.0   1.10 (0.94 to 1.29)    2.8    1.14 (0.90 to 1.46)

\*N=28 678. The number of missing values for supplementation of FA, iron, calcium and MMN were 49, 34, 130 and 50. Adjusted OR and 95% CI were derived from multivariable GEE models with random effects at county level.

†High adherence to FA supplementation was defined as starting from the periconceptional period with ≥180 days of use; high adherence to iron supplementation was considered as starting from the first trimester with ≥90 days of use; high adherence to calcium supplementation was considered as starting from the second trimester with ≥90 days of use; high adherence to MMS was defined as starting from the first trimester with ≥90 days of use.

‡Model 1 adjusted for the sociodemographic characteristics including maternal age, education, residence and income and the OR and 95% CI of these characteristics was derived from model 1.

§Model 2 adjusted for all variables in model 1 plus parity and antenatal care characteristics, and the OR and 95% CI of parity and antenatal care characteristics were derived from model 2.

¶Refers to p\<0.05.

FA, folic acid;GEE, generalised estimating equation; MMN, multiple-micronutrients.

Discussion {#s4}
==========

In this large-scale cross-sectional study, we observed that micronutrient supplements were not used as commonly as expected before and during pregnancy, and maternal adherence to micronutrient supplementation among our population, particularly in women with sociodemographic-disadvantages, was low based on the CNS and WHO recommendations. Totally, the prevalence of maternal micronutrient supplementation before and during pregnancy in Shaanxi from 2010 to 2013 was 83.9%. Compared with other countries, our overall use rate was higher than that of USA from 1999 to 2006 (77.6%),[@R2] but lower than those of Sydney, Australia in 2014 (93.8%)[@R34] and Seoul, Korea in 2012 (88%).[@R35] Compared with the domestic data, it was similar to that of Sichuan Province (81.8%) in 2010[@R4] and higher than the overall prevalence of eight Provinces of China in 2009 (66.4%).[@R20] FA, calcium, MMN and iron were the four supplements primarily used by participants.

Maternal FA supplementation is associated with the prevention of NTDs as well as the reduced risk of preterm delivery and SGA births.[@R36] Both WHO and CNS developed guidelines for promoting daily FA supplementation before and during pregnancy,[@R13] and the Chinese government also implemented the periconceptional FA supplementation to prevent NTDs since 2009. In our population, FA was the most popularly used supplement before and during pregnancy, but more than 30% of women still did not take it. Additionally, most of the users started to take FA supplements after they became pregnant and only few took FA supplements to prepare for pregnancy, which may indicate the high frequency of unplanned pregnancies or the lack of knowledge about preconceptional FA supplementation. The more serious reality was that less than 10% of women adhered to FA supplementation periconceptionally in more than 180 days. Therefore, the use of FA supplements failed to reach the recommended standards among pregnant women in Northwest China, even when maternal routine FA supplementation was strongly promoted in China.

China has a high prevalence of pregnancy anaemia, which is commonly caused by iron deficiency during pregnancy.[@R15] Reviews stated that daily iron supplementation in pregnancy could be useful in improving iron status and birth outcomes.[@R6] Only 5.4% of the participants consumed iron supplements during pregnancy, and the low rate of iron supplementation was possibly attributed to the lack of routine maternal iron supplementation guidelines in China and the popular use of antianaemic Chinese patent medicines among pregnant women in this region.[@R39] The proportion of women who had compliant iron supplementation was very low in our population (0.6% for iron and 3.2% for iron and iron-containing MMS), which is much lower than that of Western Amhara of Ethiopia (20.4% for FA-iron).[@R21] On the basis of the WHO recommendation, maternal iron supplementation should be started as early as possible during pregnancy.[@R13] Our participants usually began to use iron supplements after the periconceptional period rather than from the beginning of pregnancy. The reason may be that most women only took iron supplements under the direction of physicians after the occurrence of iron deficiency or iron deficiency anaemia during the second half of pregnancy, but prophylactic supplementation was very rare.

Maternal calcium supplementation has a clear beneficial effect on hypertension-related disorders during pregnancy and is possibly related to the reduction of preterm birth risk.[@R40] To prevent pre-eclampsia, WHO recommends daily calcium supplementation from 20 weeks of gestation for populations with low dietary calcium intake.[@R14] From the background of the low dietary calcium intake among pregnant women (512 mg/d)[@R27] and the high prevalence of preterm birth,[@R41] the WHO guideline may be suitable for widespread implementation in our population. A gap still exists between calcium supplementation among pregnant women in Northwest China and the WHO recommendation, according to the fact that more than 40% of women did not take calcium supplements during pregnancy and only 11.7% of the participants adhered to take calcium right from the start of the second trimester for more than 90 days of use.

Evidence demonstrated that periconceptional MMS with iron and FA could promote maternal health status, reduce the risk of LBW, SGA and congenital abnormalities[@R42] as well as improve the long-term intellectual development of offspring.[@R44] Developed countries like Australia had a high prevalence of periconceptional MMS (79.2%),[@R34] but the rate of MMS among our participants was 14.0%. WHO did not universally recommend MMS for pregnant women due to its potential neonatal mortality risks,[@R11] but the recent evidence showed no increased risk of neonatal mortality.[@R43] Moreover, the 2016 WHO guidelines stated that 'policy-makers in populations with a high prevalence of nutritional deficiencies might consider the benefits of MMS on maternal health to outweigh the disadvantages and may choose to give MMS that include iron and folic acid'. Comprehensively taking the situations of Shaanxi (including high incidence of adverse birth outcomes, low intake of most micronutrients from daily diet as well as from supplements and disadvantaged sociodemographic conditions among many pregnant women) into consideration, to replace iron and FA with MMS for pregnant women in low-income areas might be a useful strategy to improve overall maternal micronutrient intake in this region.[@R43]

When examining the factors associated with maternal adherence to micronutrient supplementation before and during pregnancy, we found that sociodemographic disadvantages and lower antenatal care level were associated with low adherence to micronutrient supplementation. Similar associations between educational level and prenatal health counselling with adherence to micronutrient supplementation were reported in literature.[@R10] Our finding that higher age and primiparity were predictors of compliant use of FA was consistent with that of a previous study in Ireland.[@R47] We did not find any relationship between the type of hospital for antenatal visits and FA supplementation, which may reflect the balanced implementation of national health policy on maternal FA supplementation in the health system of the study region. In our population, higher frequency of antenatal visits was associated with higher adherence to micronutrient supplementation. Aside from routine obstetric examination, women accept the phased health education from the physicians during their antenatal care visits. In addition, women planning to be pregnant or are pregnant (before 12 weeks of gestation) can receive free FA provided by the Chinese government during antenatal care visits and learn to appropriately use them under professional guidance. Iron or calcium supplementation is usually recommended to pregnant women by physicians after the diagnosis of physical or pathological changes related to iron or calcium deficiency. For women with severe pregnancy reactions or MMN deficiency, the physician may recommend MMS. Thus, higher frequency of antenatal care visits provides more opportunities for women to learn and increases the possibilities for physicians to know the pregnant women's health condition and to give recommendations in time, which finally promotes the adherence to micronutrient supplementation.

To the best of our knowledge, this is the first large-scale and representative study that investigated maternal micronutrient supplementation before and during pregnancy in Northwest China. To guarantee the representativeness, a large sample was recruited from Shaanxi Province of Northwest China using a stratified multistage random sampling method according to the proportion of rural to urban residents, population size and fertility rate in the region. The results could be generalised to other regions in Northwest China according to the similarities in terms of economy, culture, lifestyle and diet habits existing in these regions and may also reflect the universality of the low adherence to micronutrient supplementation before and during pregnancy in China. Therefore, it could serve as a basis for developing health education strategies in the future. Nonetheless, several limitations of the present study should be stated. First, this study was retrospective and all the information of micronutrient supplementation was self-reported from participants and therefore recall bias was ineluctable. Second, we did not provide an insight into the dosage of use. Although we listed the possible brands of supplements that women might consume, many women could only recall the micronutrient they used without clear commodity information. Except for FA supplements, which usually have specified dosage of 400 µg per pill, the specifications of other supplements vary from each other and thus it is difficult to calculate the accurate dosage used by our participants. However, what is certain is that some supplements women consumed were not specialised for pregnant women and thus the content of elemental iron or calcium in one tablet of the supplement is lower than the WHO recommended dosage, which may indicate the more severe situation of low adherence of micronutrient supplementation in our population. Third, the sources of recommendation regarding the use of supplements, as well as the access that women procured the supplements, were not recorded. Hence, the approach for more appropriate future interventions could not be known. More large-scale, in-depth and well-designed studies are recommended to explore the effectiveness of supplementation of iron, calcium and MMN on pregnancy outcomes according to the adherence of use and further promote the establishment of new nutritional recommendations for pregnancy in China.

Conclusion {#s5}
==========

In conclusion, maternal micronutrient supplementation before and during pregnancy in Shaanxi failed to meet the Chinese guidelines and WHO recommendation, with respect to start time and duration of use. Improving the adherence to micronutrient supplementation before or during pregnancy is still a dire issue for maternal and child health in Northwest China. Targeted health education and future guidelines of micronutrient supplementation for pregnant women should be implemented, especially for those with disadvantaged sociodemographic conditions.
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